The London Biotechnology Show 2026 will return to ExCeL London on 18โ19 November, bringing together biotechnology and pharmaceutical companies, researchers, healthcare professionals, investors and technology providers. The third annual edition is expected to attract more than 3,000 professionals and 1,600 brands, creating opportunities to explore scientific breakthroughs, commercial partnerships and emerging developments across the life sciences sector.
The conference will feature experts from leading organisations, including Pfizer, GSK, Amazon Web Services, the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England and the University of Oxford. Confirmed speakers include Dr Maria Koufali of the National Institute for Health and Care Research, Jimmy Toulas of Pfizer, Rob Harkness of GSK, Rajaram Ramanathan of Amazon Web Services, Leandro Lo Cascio of MHRA and Dr Arrash Yassaee of NHS England. Discussions will cover artificial intelligence, bioinformatics, drug discovery, gene and cell therapies, precision medicine, biopharmaceuticals and clinical research.
Click here to join our WhatsApp channel here
The exhibition will bring together global companies such as Merck, Thermo Fisher Scientific, FUJIFILM Biosciences, Abcam, Novogene and Gerresheimer, alongside emerging innovators working in radiotheranostics, cell therapy, tissue engineering and AI-enabled diagnostics. International industry associations and innovation networks will also participate, strengthening connections between research organisations, businesses and global markets.
Also read: M42 and RIT Dubai Partner on Health Informatics Training
Alongside the conference and exhibition, the event will feature a Buyer Programme and Startup Showcase. The Buyer Programme will facilitate one-to-one meetings between exhibitors and potential business customers, while the Startup Showcase will give emerging companies opportunities to present technologies and connect with investors and partners. The event aims to support collaboration and help translate biotechnology research into practical healthcare solutions and commercial opportunities.
